53
Views
6
CrossRef citations to date
0
Altmetric
Original Research

Correlation between lamivudine plasma concentrations and patient self-reported adherence to antiretroviral treatment in experienced HIV patients

, &
Pages 441-446 | Published online: 22 Nov 2011

References

  • MannheimerSFriedlandGMattsJThe consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trialsClin Infect Dis20023481115112111915001
  • PatersonDLSwindellsSMohrJAdherence to protease inhibitor therapy and outcomes in patients with HIV infectionAnn Intern Med200013310213010877736
  • GarciaRSchooleyRTBadaróRAn adherence trilogy is essential for long-term HAART successBraz J Infect Dis20037530731414552740
  • ReadTMijchAFairleyCKAdherence to antiretroviral therapy: are we doing enoughIntern Med J2003335–625425612752896
  • MunakataJBennerJSBeckerSClinical and economic outcomes of nonadherence to highly active antiretroviral therapy in patients with human immunodeficiency virusMed Care2006441089389917001259
  • TsengALCompliance issues in the treatment of HIV infectionAm J Health Syst Pharm19985517181718249775345
  • RosenbachKAAllisonRNadlerJPDaily dosing of highly active antiretroviral therapyClin Infect Dis200234568669211823957
  • RuddPAhmedSZacharyVImproved compliance measures: application in an ambulatory hypertensive drug trialClin Pharmacol Ther19904866766852147405
  • KastrissiosHSuárezJRHammerSThe extent of non-adherence in a large AIDS clinical trial using plasma dideoxynucleoside concentrations as a markerAIDS19981217230523119863873
  • YasudaJMMillerCCurrierJSThe correlation between plasma concentrations of protease inhibitors, medication adherence and virological outcome in HIV-infected patientsAntivir Ther20049575376115535413
  • ArnstenJHDemasPAFarzadeganHAntiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoringClin Infect Dis20013381417142311550118
  • SegeralOMadecYBanBSimplified assessment of antiretroviral adherence and prediction of virological efficacy in HIV-infected patients in CambodiaAIDS Res Treat2010201014207621490902
  • RomanelliFEmpeyKPomeroyCMacrocytosis as an indicator of medication (zidovudine) adherence in patients with HIV infectionAIDS Patient Care STDS200216940541112396692
  • RouetFEkoueviDKChaixMLTransfer and evaluation of an automated, low-cost real-time reverse transcription-PCR test for diagnosis and monitoring of human immunodeficiency virus type 1 infection in a West African resource-limited settingJ Clin Microbiol20054362709271715956387
  • NieuwkerkPTSprangersMABurgerDMLimited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort studyArch Intern Med2001161161962196811525698
  • ChesneyMAFactors affecting adherence to antiretroviral therapyClin Infect Dis200030Suppl 2S17117610860902
  • MurriRAmmassariAGallicanoKPatient-reported nonadherence to HAART is related to protease inhibitor levelsJ Acquir Immune Defic Syndr200024212312810935687
  • AmmassariAMurriRPezzottiPSelf-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infectionJ Acquir Immune Defic Syndr200128544544911744832
  • ZhouXJSommadossiJPRapid quantitation of (-)-2′-deoxy-3′-thiacytidine in human serum by high-performance liquid chromatography with ultraviolet detectionJ Chromatogr B Biomed Sci Appl199769124174249174279
  • MooreKHYuenGJHusseyEKPopulation pharmacokinetics of lamivudine in adult human immunodeficiency virus-infected patients enrolled in two phase III clinical trialsAntimicrob Agents Chemother199943123025302910582904
  • PanhardXLegrandMTaburetAMPopulation pharmacokinetic analysis of lamivudine, stavudine and zidovudine in controlled HIV-infected patients on HAARTEur J Clin Pharmacol200763111019102917694300
  • YuenGJLouYBumgarnerNFEquivalent steady-state pharmacokinetics of lamivudine in plasma and lamivudine triphosphate within cells following administration of lamivudine at 300 milligrams once daily and 150 milligrams twice dailyAntimicrob Agents Chemother200448117618214693537
  • HealdAEHsyuPHYuenGJPharmacokinetics of lamivudine in human immunodef iciency virus-infected patients with renal dysfunctionAntimicrob Agents Chemother1996406151415198726029
  • JohnsonMAMooreKHYuenGJClinical pharmacokinetics of lamivudineClin Pharmacokinet199936141669989342
  • WagnerGJRabkinJGMeasuring medication adherence: are missed doses reported more accurately then perfect adherence?AIDS Care200012440540811091773